Duloxetine Capsule, Delayed Release
Product Images NDC 63187-612

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63187-612). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)

A Kaplan-Meier curve showing the cumulative proportion of patients with relapse over time (days) from randomization, comparing Duloxetine treatment versus placebo. The graph depicts lower relapse rates for Duloxetine compared to placebo across approximately 200 days, illustrating treatment effect on relapse in MDD Study 5.*

FDA Label Image

Figure 2: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (gad Study 4) (Duloxetine Fig2)

A Kaplan-Meier plot showing the cumulative proportion of patients experiencing relapse over time in days from randomization, comparing Duloxetine treatment to placebo. The graph illustrates relapse rates up to around 250 days, with Duloxetine showing a lower proportion of patient relapse compared to placebo. The figure is labeled as from GAD Study 4.*

FDA Label Image

Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)

A line graph showing the percentage of patients achieving various levels of pain relief measured by 24-hour average pain severity. The x-axis indicates percent improvement in pain from baseline (0 to 100%), while the y-axis shows the percentage of patients improved (0 to 100%). Four groups are compared: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily (two lines), and placebo. The graph illustrates trends in pain relief across these groups.*

FDA Label Image

Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)

A line graph titled 'Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2' showing the percentage of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. The graph compares improvements for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo over increasing levels of pain relief.*

FDA Label Image

Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)

A line graph showing the percentage of patients achieving various levels of pain relief based on the percent improvement in pain from baseline (BOCF). The graph compares Duloxetine 60 mg/120 mg once daily to placebo, depicting higher percentages of patient improvement with Duloxetine across different pain relief thresholds.*

FDA Label Image

Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)

A line graph titled 'Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3.' The x-axis shows percent improvement in pain from baseline from greater than 0% up to 100%. The y-axis shows the percentage of patients improved, ranging from 0 to 100%. Two lines represent treatment groups: placebo (dotted line with x marks) and duloxetine 60 mg once daily (solid line with diamond marks). The duloxetine group consistently shows a higher percentage of patients improved across all levels of pain improvement compared to placebo.*

FDA Label Image

Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)

A line graph titled 'Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1' comparing placebo and duloxetine 60 mg/120 mg once daily. The x-axis shows percent improvement in pain from baseline, the y-axis shows percentage of patients improved, with duloxetine consistently showing higher patient improvement rates than placebo across the pain improvement levels.*

FDA Label Image

63187-612-60 (Duloxetine Fig9)

Label for Duloxetine 30 mg delayed-release capsules, 30-count, distributed by Citron Pharma LLC and relabeled by Proficient Rx LP. The capsule is described as a size 3 hard gelatin blue and white opaque shell with white to off-white pellets inside, imprinted with 'X' on the blue cap and '02' on the white body. Storage instructions and manufacturer details are included.*

FDA Label Image

Structure (Duloxetine Str)

Chemical structure diagram depicting the molecular structure of duloxetine hydrochloride, showing its fused aromatic rings, sulfur-containing thiophene group, and hydrochloride salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.